Something rotten in the state of clinical and economic evaluations?
Open Access
- 1 March 1994
- journal article
- editorial
- Published by Wiley in Health Economics
- Vol. 3 (2), 63-67
- https://doi.org/10.1002/hec.4730030202
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.BMJ, 1993
- Consensus conferences as drug promotionThe Lancet, 1993
- Getting to grips with Archie Cochrane's agenda.BMJ, 1992
- Selective serotonin reuptake inhibitors.BMJ, 1992
- Economic Analysis in Randomized Control TrialsMedical Care, 1992
- Australian Guidelines for Cost-Effectiveness Studies of PharmaceuticalsPharmacoEconomics, 1992
- A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patientsThe British Journal of Psychiatry, 1991
- Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical CompaniesNew England Journal of Medicine, 1991
- Publication bias in clinical researchThe Lancet, 1991
- Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations A report by the Canadian task force on the periodic health examinationJournal of Clinical Epidemiology, 1990